CA2064481C - Method of producing .alpha.,.beta.-unsaturated ketolactones - Google Patents
Method of producing .alpha.,.beta.-unsaturated ketolactonesInfo
- Publication number
- CA2064481C CA2064481C CA002064481A CA2064481A CA2064481C CA 2064481 C CA2064481 C CA 2064481C CA 002064481 A CA002064481 A CA 002064481A CA 2064481 A CA2064481 A CA 2064481A CA 2064481 C CA2064481 C CA 2064481C
- Authority
- CA
- Canada
- Prior art keywords
- group
- halogen atom
- alkyl group
- aldehyde
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- -1 bicyclolactone aldehyde Chemical class 0.000 claims abstract description 15
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 11
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims abstract description 9
- 150000003752 zinc compounds Chemical class 0.000 claims abstract description 7
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims abstract description 6
- 150000008046 alkali metal hydrides Chemical class 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 abstract description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 5
- 239000007858 starting material Substances 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 150000002596 lactones Chemical class 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000006859 Swern oxidation reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- CISDEVRDMKWPCP-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluoroheptan-2-one Chemical compound CCCCC(F)(F)C(=O)CP(=O)(OC)OC CISDEVRDMKWPCP-UHFFFAOYSA-N 0.000 description 2
- SQRDEVDPDGSBGC-UHFFFAOYSA-N 4,7,7-trimethyl-3-oxabicyclo[2.2.1]heptan-2-one Chemical compound C1CC2(C)OC(=O)C1C2(C)C SQRDEVDPDGSBGC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003476 thallium compounds Chemical class 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BCRKBAANNQLPBT-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluorononan-2-one Chemical compound CCCCCCC(F)(F)C(=O)CP(=O)(OC)OC BCRKBAANNQLPBT-UHFFFAOYSA-N 0.000 description 1
- BUBVLQDEIIUIQG-UHFFFAOYSA-N 3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-one Chemical compound C=1C=CC=CC=1COC1C(OCC=2C=CC=CC=2)C(OCC=2C=CC=CC=2)C(=O)OC1COCC1=CC=CC=C1 BUBVLQDEIIUIQG-UHFFFAOYSA-N 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- 238000006804 Parikh-Doering oxidation reaction Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- DZFYOYRNBGNPJW-UHFFFAOYSA-N ethoxythallium Chemical compound [Tl+].CC[O-] DZFYOYRNBGNPJW-UHFFFAOYSA-N 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Furan Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP71483/1991 | 1991-04-04 | ||
| JP7148391 | 1991-04-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2064481A1 CA2064481A1 (en) | 1992-10-05 |
| CA2064481C true CA2064481C (en) | 1996-12-24 |
Family
ID=13461939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002064481A Expired - Fee Related CA2064481C (en) | 1991-04-04 | 1992-03-31 | Method of producing .alpha.,.beta.-unsaturated ketolactones |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5229529A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0507625B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JPH089608B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR970003125B1 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE141921T1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2064481C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69213067T2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK0507625T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2093776T3 (cg-RX-API-DMAC10.html) |
| GR (1) | GR3020903T3 (cg-RX-API-DMAC10.html) |
| TW (1) | TW197439B (cg-RX-API-DMAC10.html) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0643051B1 (en) * | 1992-09-30 | 2000-01-26 | R-Tech Ueno, Ltd. | Process for Producing Alfa, Beta-Unsaturated Ketones |
| CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
| JP4358940B2 (ja) * | 1999-08-26 | 2009-11-04 | 丸善石油化学株式会社 | シクロヘキサンラクトン構造を有する重合性化合物及び重合体 |
| CA2307393A1 (en) | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US20030157170A1 (en) * | 2001-03-13 | 2003-08-21 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| CA2440935A1 (en) | 2001-03-13 | 2002-09-19 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
| PT1392254E (pt) * | 2001-04-20 | 2007-06-29 | Univ British Columbia | Sistemas de distribuição micelares de fármacos para fármacos hidrofóbicos. |
| US20030216758A1 (en) * | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
| DE10220729A1 (de) * | 2002-05-08 | 2003-11-20 | Martin Foerster | Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| CA2511521C (en) | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| WO2005016241A2 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
| US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| US7846940B2 (en) * | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| MX2007001589A (es) * | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
| WO2006089218A2 (en) * | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
| US20070073385A1 (en) * | 2005-09-20 | 2007-03-29 | Cook Incorporated | Eluting, implantable medical device |
| CA2819844C (en) * | 2006-02-07 | 2015-09-15 | R-Tech Ueno, Ltd. | Prostaglandin derivatives |
| CA2646156C (en) | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| WO2008005284A2 (en) | 2006-06-30 | 2008-01-10 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
| US20080241215A1 (en) * | 2007-03-28 | 2008-10-02 | Robert Falotico | Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke |
| US8420110B2 (en) | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
| US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
| US8273404B2 (en) | 2008-05-19 | 2012-09-25 | Cordis Corporation | Extraction of solvents from drug containing polymer reservoirs |
| EP2859916B1 (en) | 2008-05-22 | 2017-11-29 | Galera Labs, LLC | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy |
| WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
| US8642063B2 (en) | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
| US8513441B2 (en) * | 2008-08-29 | 2013-08-20 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
| ES2477552T3 (es) | 2008-09-08 | 2014-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos |
| US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| US8389522B2 (en) | 2008-10-28 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
| CA2750487A1 (en) | 2009-01-22 | 2010-07-29 | Apotex Pharmachem Inc. | Methods of making lubiprostone and intermediates thereof |
| US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| US20120302954A1 (en) | 2011-05-25 | 2012-11-29 | Zhao Jonathon Z | Expandable devices coated with a paclitaxel composition |
| US20120303115A1 (en) | 2011-05-25 | 2012-11-29 | Dadino Ronald C | Expandable devices coated with a rapamycin composition |
| US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
| EP2874650A4 (en) | 2012-07-19 | 2016-03-23 | Redwood Bioscience Inc | FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF |
| CN104884056A (zh) | 2012-11-12 | 2015-09-02 | 雷德伍德生物科技股份有限公司 | 用于制备缀合物的化合物和方法 |
| KR102132246B1 (ko) | 2013-02-15 | 2020-07-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法 |
| AU2014354643B2 (en) | 2013-11-27 | 2020-03-05 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
| US10517961B2 (en) | 2015-09-25 | 2019-12-31 | ZY Therapeutics, Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| US10654875B2 (en) | 2015-11-12 | 2020-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| EP3448885A4 (en) | 2016-04-26 | 2020-01-08 | R.P. Scherer Technologies, LLC | ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| IL312621A (en) | 2016-06-01 | 2024-07-01 | Servier Ip Uk Ltd | Compositions of polyalkylene oxide-asparaginase and methods for their preparation and use |
| TWI852903B (zh) | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| CN110177808A (zh) | 2017-01-18 | 2019-08-27 | F1肿瘤医学公司 | 针对axl或ror2的嵌合抗原受体及其使用方法 |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| EP3630189A4 (en) | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | LINKER FOR ANTIBODY MEDICINAL CONJUGATES |
| JP2021512110A (ja) | 2018-01-31 | 2021-05-13 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 |
| WO2019195596A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| EP3773632A4 (en) | 2018-04-06 | 2022-05-18 | The Regents of The University of California | Methods of treating egfrviii expressing glioblastomas |
| JP2021521173A (ja) | 2018-04-11 | 2021-08-26 | オハイオ・ステイト・イノベーション・ファウンデーション | 眼内薬物送達用の持続放出微粒子のための方法及び組成物 |
| EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
| WO2020148612A1 (en) | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US11685904B2 (en) | 2019-02-14 | 2023-06-27 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CN113692413A (zh) | 2019-04-02 | 2021-11-23 | 肯乔克蒂生物技术股份有限公司 | 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法 |
| BR112022011158A2 (pt) | 2019-12-12 | 2022-08-30 | Ignite Immunotherapy Inc | Vírus vaccinia oncolítico variante e métodos de uso do mesmo |
| MX2022009355A (es) | 2020-01-29 | 2022-09-02 | Kenjockety Biotechnology Inc | Anticuerpo anti-mdr1 y uso del mismo. |
| JP7768902B2 (ja) | 2020-06-04 | 2025-11-12 | ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 | Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法 |
| US20230212305A1 (en) | 2020-06-04 | 2023-07-06 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
| AU2021310520A1 (en) | 2020-07-14 | 2023-02-16 | Pfizer Inc. | Recombinant vaccinia virus |
| CA3193588A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
| AU2021380659A1 (en) | 2020-11-13 | 2023-06-01 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| AU2021382033A1 (en) | 2020-11-20 | 2023-06-22 | R.P. Scherer Technologies, Llc | Glycoside dual-cleavage linkers for antibody-drug conjugates |
| EP4448007A1 (en) | 2021-12-13 | 2024-10-23 | William Robert Arathoon Living Trust Dated August 29, 2016 | Anti-abcb1 antibodies |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4032576A (cg-RX-API-DMAC10.html) * | 1976-01-08 | 1977-06-28 | ||
| DE2655004C3 (de) * | 1976-12-02 | 1980-06-19 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von bicyclischen Laktonen |
| EP0219580B1 (en) * | 1985-09-18 | 1989-11-29 | The Upjohn Company | Stereo-selective reduction |
| JPS62153259A (ja) * | 1985-12-26 | 1987-07-08 | Sagami Chem Res Center | （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法 |
| DE3620442A1 (de) * | 1986-06-18 | 1987-12-23 | Merck Patent Gmbh | Ketolactone |
| DE3888542T2 (de) * | 1987-09-04 | 1994-07-21 | Upjohn Co | Verfahren zur herstellung von prostaglandinzwischenprodukten. |
-
1992
- 1992-03-28 TW TW081102387A patent/TW197439B/zh active
- 1992-03-30 JP JP4073782A patent/JPH089608B2/ja not_active Expired - Lifetime
- 1992-03-31 CA CA002064481A patent/CA2064481C/en not_active Expired - Fee Related
- 1992-04-01 US US07/861,518 patent/US5229529A/en not_active Expired - Lifetime
- 1992-04-03 DK DK92302992.0T patent/DK0507625T3/da active
- 1992-04-03 ES ES92302992T patent/ES2093776T3/es not_active Expired - Lifetime
- 1992-04-03 EP EP92302992A patent/EP0507625B1/en not_active Expired - Lifetime
- 1992-04-03 AT AT92302992T patent/ATE141921T1/de not_active IP Right Cessation
- 1992-04-03 DE DE69213067T patent/DE69213067T2/de not_active Expired - Fee Related
- 1992-04-04 KR KR1019920005662A patent/KR970003125B1/ko not_active Expired - Fee Related
-
1996
- 1996-08-29 GR GR960402124T patent/GR3020903T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2093776T3 (es) | 1997-01-01 |
| KR920019771A (ko) | 1992-11-20 |
| DE69213067T2 (de) | 1997-01-16 |
| TW197439B (cg-RX-API-DMAC10.html) | 1993-01-01 |
| DK0507625T3 (da) | 1996-09-16 |
| US5229529A (en) | 1993-07-20 |
| DE69213067D1 (de) | 1996-10-02 |
| EP0507625A1 (en) | 1992-10-07 |
| JPH0592965A (ja) | 1993-04-16 |
| JPH089608B2 (ja) | 1996-01-31 |
| ATE141921T1 (de) | 1996-09-15 |
| GR3020903T3 (en) | 1996-11-30 |
| KR970003125B1 (ko) | 1997-03-14 |
| CA2064481A1 (en) | 1992-10-05 |
| EP0507625B1 (en) | 1996-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2064481C (en) | Method of producing .alpha.,.beta.-unsaturated ketolactones | |
| US5874581A (en) | 2-silyloxy-tetrahydrothienopyridine, salt thereof and process for preparing the same | |
| GB2033904A (en) | Dihydrobenzopyrans and thiopyrans | |
| HU196595B (en) | Process for producing (2,3-trans)-tetrahydro-5-hydroxy-3-hydroxy-methyl-2-phenyl-furan derivatives | |
| US5043446A (en) | Process for the preparation of pterin derivatives | |
| KR100369274B1 (ko) | 4-히드록시-2-피롤리돈의개량제법 | |
| CA1117127A (en) | Derivatives of 3-azabicyclo(3.1.0)hexane and a process for their preparation | |
| EP0243646B1 (en) | A process for the preparation of forskolin from 9-deoxy-forskolin and intermediates used therein | |
| US4191823A (en) | Process for the preparation of oxaprostaglandin intermediates | |
| EP0532218B1 (en) | Process for production of prostaglandin intermediates | |
| HU184917B (en) | Process for preparing 7-substituted pgi down 2 derivatives | |
| JP3135658B2 (ja) | ラクトン誘導体の新規製造方法 | |
| JPH05286894A (ja) | カルボン酸エステル又はカルボン酸チオエステルの新規製造方法 | |
| US5079371A (en) | Process for production of prostaglandin intermediates | |
| US4808340A (en) | Process for preparing methyl 4-oxo-5-tetradecynoate | |
| US4140863A (en) | 9,11-Dihalo-PG2 compounds | |
| GB1589200A (en) | Prostaglandin derivatives | |
| KR810001248B1 (ko) | 시클로펜탄올의 락톤유도체의 제조방법 | |
| JPH0379360B2 (cg-RX-API-DMAC10.html) | ||
| US5374745A (en) | Process for the synthesis of propargyl alcohols and their use for production of prostaglandin precursors | |
| US4283575A (en) | 2-Decarboxy-2-hydroxymethyl-19-hydroxy-6a-carba-PGI2 compounds | |
| US4212984A (en) | Prostaglandin precursors | |
| HU180705B (hu) | Eljárás új 4-ariltiometil-2H-ciklopentano[b]furán-származékok előállítására | |
| US4922032A (en) | Process for the preparation of optically active 2-methyl-1,2-hexanediols | |
| CN115485270A (zh) | 用于制备手性前列腺素烯醇中间体的方法和可用于该方法的中间体化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |